Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Latest Biotechnology and Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings, Inc. Stock News

As of September 1, 2026, Ultragenyx Pharmaceutical Inc. had a $2.5 billion market capitalization, compared to the Biotechnology median of $282.5 million. Ultragenyx Pharmaceutical Inc.’s stock is NA in 2026, NA in the previous five trading days and down 13.85% in the past year.

Currently, Ultragenyx Pharmaceutical Inc. does not have a price-earnings ratio. Ultragenyx Pharmaceutical Inc.’s trailing 12-month revenue is $717.0 million with a -81.7% net profit margin. Year-over-year quarterly sales growth most recently was 28.1%. Analysts expect adjusted earnings to reach $-3.846 per share for the current fiscal year. Ultragenyx Pharmaceutical Inc. does not currently pay a dividend.

Currently, Maravai LifeSciences Holdings, Inc. does not have a price-earnings ratio. Maravai LifeSciences Holdings, Inc.’s trailing 12-month revenue is $208.8 million with a -37.1% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $-0.181 per share for the current fiscal year. Maravai LifeSciences Holdings, Inc. does not currently pay a dividend.

How We Compare Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc. Stock Value Grades

Company	Ticker	Value
Ultragenyx Pharmaceutical Inc.	RARE	na
Maravai LifeSciences Holdings, Inc.	MRVI	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Ultragenyx Pharmaceutical Inc. does not have a meaningful Value Score. Maravai LifeSciences Holdings, Inc. has a Value Score of 13, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to value.

Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc.’s Momentum Grades

Company	Ticker	Momentum
Ultragenyx Pharmaceutical Inc.	RARE	D
Maravai LifeSciences Holdings, Inc.	MRVI	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Ultragenyx Pharmaceutical Inc. has a Momentum Score of 40, which is Weak. Maravai LifeSciences Holdings, Inc. has a Momentum Score of 96, which is Very Strong.

The Momentum Grade Winner: Maravai LifeSciences Holdings, Inc.

As you can clearly see from the Momentum Grade breakdown above, Maravai LifeSciences Holdings, Inc. is considered to have stronger momentum compared to Ultragenyx Pharmaceutical Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Maravai LifeSciences Holdings, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Ultragenyx Pharmaceutical Inc.	RARE	C
Maravai LifeSciences Holdings, Inc.	MRVI	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Ultragenyx Pharmaceutical Inc. has a Earnings Estimate Score of 56, which is Neutral. Maravai LifeSciences Holdings, Inc. has a Earnings Estimate Score of 37, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to estimate revisions.

Other Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc. Grades

In addition to Momentum, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings or Inc. Stock?

Overall, Ultragenyx Pharmaceutical Inc. stock has a Value Score of , Momentum Score of 40 and Estimate Revisions Score of 56.

Maravai LifeSciences Holdings, Inc. stock has a Value Score of 13, Momentum Score of 96 and Estimate Revisions Score of 37.

Comparing Ultragenyx Pharmaceutical Inc., Maravai LifeSciences Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.